Company overview
Telesis Bio provides end-to-end automated solutions for rapid, on-site synthesis of high-fidelity synthetic DNA and mRNA, eliminating outsourcing delays in pharmaceutical R&D. Key platforms include the BioXp system for overnight gene and mRNA construction and the Gibson SOLA platform for enzymatic synthesis integrated with lab automation. These tools support therapeutic discovery, vaccine development, and synthetic biology workflows in customer labs.
Telesis Bio is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include dna synthesis, mrna synthesis, synthetic biology, bioxp system, gibson sola.
Products and technologies associated with Telesis Bio include Synthesis — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://telesisbio.com
- Markets served
- United States & Americas
- Keywords
- dna synthesis, mrna synthesis, synthetic biology, bioxp system, gibson sola
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Telesis Bio's main products for DNA and mRNA synthesis?
- Telesis Bio offers the BioXp system, the world's only synthetic biology workstation that builds DNA and mRNA overnight, and the Gibson SOLA platform for on-demand, high-fidelity enzymatic synthesis directly in labs.
- What applications do Telesis Bio solutions support in pharma R&D?
- Solutions enable cell-free production of DNA and mRNA for therapeutic discovery, vaccine development, diagnostic tests, agricultural biotech, and industrial chemicals, accelerating workflows across synthetic biology.
- Does Telesis Bio support on-premise synthesis and integrations?
- Yes, platforms like Gibson SOLA integrate with lab automation such as Beckman Coulter's Biomek Echo One for scalable, on-premise DNA and mRNA synthesis, boosting productivity without outsourcing.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
